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Retinoic acid (RA) is one of the principal active metabolites of vitamin A (retinol) which mediates a spectrum
of critical physiological and developmental processes.Transcriptional regulation by RA is mediated primarily
by members of the retinoic acid receptor (RAR) subfamily of the nuclear receptor (NR) superfamily of
transcription factors. NRs bind specific genomic DNA sequence motifs and engage coregulators and
components of the basal transcription machinery to effect transcriptional regulation at target gene promoters.
Disruption of signaling by retinoic acid is thought to underlie the etiology of a number of inflammatory and
neoplastic diseases including breast cancer and haematological malignancies. A meeting of international
researchers in retinoid signaling was convened in Strasbourg in September 2011 under the auspices of the
European Molecular Biology Organization (EMBO). Retinoids 2011 encompassed myriad mechanistic, biological
and pathological aspects of these hormones and their cognate receptors, as well as setting these advances
in the context of wider current questions on signaling by members of the NR superfamily.
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Introduction
Vitamin A, or retinol, is an essential nutrient for
vertebrates. Retinoic acid (RA), the major bioactive
metabolite of retinol, is a morphogen with pleiotropic roles
in cell growth and differentiation in embryonic
development and adult physiology [Chambon, 1996; Mark
et al., 2009]. A number of key proteins and enzymes
control retinoid metabolism and regulate the bioavailability
of retinoic acid to its target cells. Serum retinol-binding
proteins (RBPs) and cellular retinol binding proteins
(CRBPs) transport retinol in the serum and cells; retinol
dehydrogenases (RDHs) and retinal dehydrogenases
(RALDHs) mediate the biosynthesis of RA from dietary
vitamin A, the latter group of enzymes catalyzing the rate
limiting step in RA biosynthesis; and the cellular RA
binding proteins (CRABPs) mediate the uptake of RA in
target cells.
RA signaling in its target cells occurs primarily through
binding to members of the retinoic acid receptor (RAR)
subfamily of the nuclear receptor (NR) superfamily of
ligand-activated transcription factors [Aagaard et al., 2011;
Tsai and O'Malley, 1994], namely RARα, RARβ and
RARγ. Like other NRs, RARs contain a domain that
mediates interaction with all-trans RA (the ligand binding
domain, or LBD), a zinc finger-containing DNA binding
domain (DBD) that binds to RA response elements
(RAREs) in target genes; and a dimerization domain that
engages members of the retinoid X receptor (RXR)
subfamily in RXR/RAR heterodimers [Rochette-Egly and
Germain, 2009]. RA-bound RARs effect transcriptional
regulation by recruitment of coactivators and the
subsequent assembly of a transcriptional preinitiation
complex at target gene promoters [McKenna and
O'Malley, 2002]. In contrast, in the absence of RA,
unliganded RARs exert repressive effects on target gene
promoters by recruitment of corepressor complexes.
Central to this model is the engagement by RARs of
epigenetic modifiers of promoter chromatin architecture,
creating alternately permissive and restrictive
environments for transcriptional initiation [Martens et al.,
2011]. In addition to direct genomic effects via RARs, RA
is known to engage cellular signaling pathways that
mediate pre-genomic kinase cascades that also ultimately
effect regulation of gene expression.
The myriad mechanistic and biological facets of retinoid
signaling pathways, and the pathologies associated with
their disruption, were the focus of a recent European
Molecular Biology Organization (EMBO)-sponsored
conference held at the Institut de Génétique et de Biologie
Moléculaire et Cellulaire (IGBMC) in Strasbourg, France,
on September 22-24
th, 2011.The conference brought
together researchers from a wide variety of disciplines,
including phylogenetics, cell biology, biochemistry,
structural biology, developmental biology and clinical
practice, who collectively conveyed a keen appreciation
of the fundamental roles played by retinoids and RARs,
as well as other members of the NR superfamily, in
orchestrating programs of transcriptional regulation
required for the integrity of cellular growth and
differentiation.
Keynote Lecture: Michael G. Rosenfeld
Many models of tumor development invoke random DNA
translocation events which confer selective growth
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(UCSD, La Jolla, USA) proposed an alternative model
of tumor translocation in which non-random, induced DNA
translocation events result in cell proliferation and
selection. TMPRSS2 is an androgen-regulated gene
located on human chromosome 21q22.3 that encodes
an enzyme of the serine protease family.The human
ERG gene, also at 21q22.3, encodes a member of the
erythroblast transformation-specific (ETS) family of
transcription factors. Up to 70% of all prostate tumors
have a specific fusion of TMPRSS2 and ERG. Rosenfeld
described work showing that dihydrotestosterone
(DHT)-induced spatial proximity, involving nuclear myosin
I-dependent motors, was required for interchromosomal
translocation between TMPRSS2 and ERG in prostate
tumors.The induced double-stranded DNA break sites
were localized to intronic regions of the gene translocation
partners, and were shown to involve the association of
androgen receptor (AR) with an AID/Gadd45 complex,
the recruitment of which was abolished by selective AR
modulators (SARMs). Gadd45/GADD45A is a member
of the Gadd45 family of acidic nuclear proteins, which
also contains MyD118 and CR6, whose transcript levels
are increased following exposure of cells to stress
conditions and treatment with DNA-damaging agents.
While Rosenfeld’s observations were made in the context
of tumor translocation events, the invocation of long
distance DNA-DNA interactions in the context of AR
action has exciting implications for the model of regulation
of gene expression by this receptor and conceivably other
members of the NR superfamily.
PIWIL1 is a member of the PIWI subfamily of Argonaute
proteins, which play important roles in stem cell
self-renewal, RNA silencing and translational regulation
in diverse organisms. Sketching a model casting
corepressors as protectors against translocation events
in cancer, Rosenfeld drew attention to decreased levels
of PIWIL1 in LNCaP prostate cancer cells. Supporting
such a notion, he described experiments showing that
translocation events attributable to genotoxic stress were
increased in the context of PIWIL1 knockdown and
decreased in the context of PIWIL1 overexpression,
observations that appeared to apply generally to other
translocations in addition to TMPRSS2/ERG. Rosenfeld
briefly alluded to a chemical library screen for inhibitors
of translocation using expression of fusion transcripts as
a readout and focused on one particular hit, SD70, that
was shown to bind to the active site of lysine demethylase
4C (KDM4C). Rosenfeld proceeded to describe a
3-dimensional DNA annealing, selection and ligation
(DASL) strategy that had been used to show that
E2-induced binding of estrogen receptor α (ERα) to target
gene enhancers causes activation through induction of
bidirectional non-coding RNA (ncRNA) transcripts and
short range enhancer-promoter looping. In support of this,
the SD70 compound, which had earlier been shown to
inhibit translocation events, inhibited 17βE2 induction of
target genes.The principle of DNA breakage events
playing a key role in NR-mediated regulation of gene
expression developed into a recurring theme throughout
the meeting, and would later feature in talks by Pierre
Chambon and Jean-Marc Egly (IGBMC, Strasbourg,
France).
While retinoids are well-known inducers of stem cell
differentiation, the cellular mechanisms underlying this
biology are unclear. Rosenfeld showed that RA treatment
of human stem cell lines, such as Ntera-2, but not stem
cell lines from other species, induced RNA Polymerase
III-regulated DR2 Alu transcripts.These transcripts were
stabilized through an interaction with Ago3, a member of
the Argonaute AGO subfamily, and accumulated in
cytoplasmic P bodies, where they underwent
Dicer-dependent processing and mediated degradation
of specific stem cell mRNAs and subsequent exit from
the stem cell state (Figure 1). A biochemical strategy to
identify Ago3-interacting proteins implicated EDC4 in the
assembly of a decapping complex and the subsequent
degradation of the stem cell RNAs, leading to inhibition
of stem cell proliferation and progression to a neuronal
stem cell fate. Placing his results in a broader context,
Rosenfeld speculated that by dint of their sheer numbers
– approximately 3500 identified to date – non-coding
RNAs were eminently positioned to function as global
modulators of the regulation of gene expression by
multiple classes of transcription factors.
Figure 1.  Role of non-coding RNAs in RA signaling during neuronal
differentiation. RA induces a RAR, PolIII-dependent activation of DR2
Alu repeats in embryonic stem cells, generally adjacent to active PolII
transcription units, and these transcripts are processed and serve to cause
Ago3-dependent degradation of stem cell mRNAs harboring
complementary sequences, with biological effects on signal-dependent
exit from the stem cell state.
Special Plenary Lecture: Pierre
Chambon
Glucocorticoids are one of the most widely prescribed
prescription drug classes and have applications in a broad
range of therapeutic indices, including cancer,
osteoporosis and inflammatory disorders such as asthma
and eczema.Their anti-inflammatory properties derive in
part from the ability of agonist-bound GR to effect
transrepression of transcription factors such as AP-1,
which are key components of the inflammatory signaling
response (Figure 2). Despite their clinical success, the
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restricted their more widespread use, and the pursuit of
dissociated glucocorticoids, which retain the beneficial
anti-inflammatory properties at the expense of undesirable
side effects of GR transactivation, is the subject of
intensive investigation in the pharmaceutical industry.
Pierre Chambon (IGBMC, Strasbourg, France)
described studies into an inflammatory skin condition that
shed light on fundamental mechanisms of transcriptional
regulation by GR and other NRs.
Figure 2.  Beneficial and undesirable clinical effects of
glucocorticoids are mediated by distinct transcriptional mechanisms.
See text for details.
Human atopic dermatitis (AD) is a familial skin condition
affecting up to 20% of children and 3% of adults in
Western society and is characterized by erythema, scaling
and epidermal hyperplasia, among other symptoms.While
glucocorticoid therapy is effective for the disease, chronic
treatments using these drugs carry with them debilitating
side-effects. Reviewing previous findings in his laboratory
[Li et al., 2009; Li et al., 2006], Chambon described a
mouse model, in which RXRα and RXRβ were selectively
ablated in epidermal keratinocytes, that developed a skin
and systemic syndrome mimicking AD that was
attributable to ectopic expression of the inflammatory
cytokine thymic stromal lymphopoietin (TSLP). Under
normal physiological conditions in epidermal
keratinocytes, multiple signaling pathways exert
repressive effects on the TSLP promoter. Unliganded
RXRα/VDR and RXRβ/RARγ heterodimers, for example,
were shown to bind to VDREs (DR3-d, DR3-f and DR3-g)
and a RARE (DR2-b) respectively, in the upstream region
of the TSLP promoter. However, topical treatment with
vitamin D3 or its hypocalcemic analog MC903, along with
RA, results in the clearance of corepressors and
recruitment assembly of coactivators to the TSLP
promoter, induction of the gene and generation of an
AD-like condition.The pivotal role of TSLP in the etiology
of AD led Chambon to speculate whether the beneficial
effects of glucocorticoid therapy in AD might be mediated
in part by repression of TSLP. He demonstrated that the
GR agonist fluocinolone acetonide repressed TSLP in
epidermal keratinocytes in a GR-dependent manner. A
tandem manual and bioinformatically-assisted search of
the TSLP promoter identified an IR1 (consensus inverted
repeat separated by a single nucleotide) that was shown
to bind liganded GR in vivo, along with a cadre of
corepressors and associated repressive histone writers,
including HDAC2 and HDAC3. Referring to this sequence
as an inverted repeat negative GRE (IR nGRE), he
described a chromosome conformation capture assay,
similar to that discussed earlier by Rosenfeld, which
demonstrated that binding of GR to the nGRE precluded
looping of the region containing the activating VDRE with
the proximal promoter and subsequent initiation of
transcription. Placing the mechanistic studies in a wider
clinical context, Chambon noted not only that side effects
of glucocorticoid-based therapy were attributable in
certain cases to nGRE-dependent repression, but that
available dissociated glucocorticoids retained the ability
to directly transrepress through IR nGREs.These
provocative findings have profound consequences for the
direction of efforts to fine-tune glucocorticoid therapy, and
point to the possible development of a new class of
“improved” dissociated GCs which lack all GR functions,
including transactivation and direct transrepression
through nGREs, but not tethered transrepression [Surjit
et al., 2011].
Phylogeny of retinoid signaling
While the evolutionary functions of RARs have been well
studied in chordates, outside this phylum, evidence for
roles of RA signaling is scarce and the evolutionary origin
of the RA pathway itself thus remains elusive. Vincent
Laudet (IGFL, Lyon, France) highlighted the great
variability in the NR complement of different organisms
in the same subphyla.While vertebrates, he observed,
have 50 NR genes, fish have up to 70; similarly,
invertebrates share 25 known receptor genes, but
nematodes have 250, while sponges have only a pair.
Laudet suggested that NR phylogeny, placed in the
context of metazoan evolution, was needed to detect NR
orthologs. Such an approach was used to show that the
genome of the Urbilaterian, the hypothetical last common
ancestor of the bilaterian clade, contained about 25 NR
genes, considerably more than anticipated.This number
included orthologs of liganded receptors, which were
previously thought to be specific to vertebrates. Moreover,
he suggested that the NR phylogenetic tree, previously
comprising 6 known subfamilies, could be updated to
include 3 new subfamilies, namely NR7, NR8 and NR9,
which are present in molluscs and annelids, but which
have been lost in Drosophila, nematodes and vertebrates.
Laudet suggested that the ancestral NR was most likely
to be a low affinity fatty acid sensor (Figure 3).Turning
to a discussion of the evolution of retinoid signaling, he
pointed out that the DNA binding domains of metazoan
RARs and RXRs are well conserved, and the RAR/RXR
heterodimer was present in ancestral bilaterians. Laudet
highlighted the good conservation of residues contacting
RA in the LBD of RARs from various metazoans, although
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more variability than those of vertebrates. Laudet stressed
the fact that there is a marked difference between the
species tree and the NR tree: ultraspiracle in locusts, for
example, is more similar to its human ortholog than that
in Drosophila.
Classical models of retinoid signaling
Classical retinoid signaling involves the RAR-mediated
transcriptional activation or repression of target genes in
response to the presence or absence of RA.The binding
of retinoic acid to RARs results in their formation of
heterodimers with RXRs and their interaction with RAREs
in the enhancer regions of target genes, primarily direct
repeats separated by one (DR1), two (DR2) or five (DR5)
nucleotides.These heterodimers associate with
coactivator complexes and effect long-distance
communications with the promoters of target genes,
culminating in the recruitment of basal transcription factors
such as TFIIH, the stabilization of a RNA Polymerase
II-nucleated preinitiation complex and the transcription of
these genes. In contrast, the establishment of repressive
complexes in the absence of agonist is associated with
silencing of target genes. Interactions of coregulators with
NRs are known to involve specific α-helical sequences
referred to as NR boxes, or LXXLL motifs in the case of
coactivators [Heery et al., 1997] and CoRNR boxes in
the case of corepressors [Hu and Lazar, 1999]. A solid
body of evidence supports the notion that acetylation and
methylation reactions catalyzed by coregulator-associated
enzymes target a variety of substrates, including histones,
and contribute to specific epigenomic signatures across
target promoters that are critical determinants of their
transcriptional productivity.
Ligand, receptor and coregulator interactions
Small angle X-ray scattering (SAXS) and small angle
neutron scattering (SANS) are complementary techniques
used for structural characterization of crystallized
molecules that yield data in the nanometer range. Dino
Moras (IGBMC, Strasbourg, France) discussed a series
of SAXS and SANS-based crystal structures of RARβ in
solution that painted an intimate portrait of this receptor’s
association with several coregulators. Moras observed
that while the RARβ LBD was stable as a monomer in
solution (Figure 4A), the functional form in vitro was a
heterodimer with a member of the RXR subfamily. He
demonstrated that the stoichiometry of the interaction of
MED1/TRAP220 with RARβ was 1 coregulator:1
RARβ/RXR heterodimer (Figure 4B) – a ratio that held
true for other coregulators such as SRC-1/NCOA1 and
TIF2/NCOA2, and that mutation of the RXR moiety had
no effect on the binding of TRAP220/MED1 to the
heterodimer. By inducing asymmetry in the complex, DNA
sequence and spacing proved to be critical modulators
of the association of coactivator with receptor, suggesting
a structural basis for the well-known effect of promoter
context on receptor and coactivator function [Korzus et
al., 1998]. Moras went on to show that in solution, RAR
homodimers were asymmetrical, and that ligand alone
did not induce dimerization and that the presence of a
coactivator peptide established an equilibrium between
the RARβ monomer and heterodimer. Moreover, in the
context of a longer domain of SRC-1, the dimeric form
was even more stable, such that a complex comprising
RARβ and a 20kD SRC-1 receptor interaction domain
(RID) was principally in the dimeric form. Moras sketched
a model in which binding of coactivator induces a
conformational change in the liganded LBD, resulting in
increased stability of the dimeric form, and in which
negative co-operativity reduces the affinity of the complex
for a second coactivator moiety (Figure 3).
While the centrality of coregulator exchange as a general
mechanism in the dual activation and repressive
transcriptional properties of NRs has been accepted for
over a decade [Glass and Rosenfeld, 2000],
structure-function studies probing the molecular basis of
RAR-coregulator interactions have been few in number.
William Bourguet (Montpelier, France) described a
number of crystallographic studies of RARs which
illuminated the role of specific interaction interfaces on
both receptor and corepressor in mediating gene
silencing. Bourguet pointed out that RARs possess a
strong basal repression function which RARα antagonists
such as BMS614 can induce by disrupting the coactivator
recognition surface of RARα by displacing helix H12.
Bourguet presented two structures representing the
opposing functionalities of RARα, a repressive form in
complex with the antagonist BMS493 and CoRNR1 of
SMRT/NCOR2 (to which RARα exhibits preferential
binding), and an active form in complex with the agonist
Am580 and an LXXLL motif-containing peptide.While
broad similarities are evident between the two structures,
they are distinguishable by secondary structures adopted
by residues in helix H12 of the receptor, namely α-helical
in the active form and adopting a predominantly β-strand
character in the repressive form (Figure 5). Bourguet
proceeded to discuss mammalian two-hybrid data
indicating that residues adopting a β-strand conformation
in CORNR1 were essential for corepressor/RAR
interactions. Similarly, residues in β-strand 3 (S3) of the
RARα LBD were critical for corepressor recruitment: a
single mutation (I396E) prevents corepressor binding
while preserving coactivator recruitment in the presence
of agonist, and confers a much higher basal activation
function than that of the wild type receptor. Bourguet
suggested that by uncoupling the repressive and
activational functions of RARα, the I396E mutant might
be a valuable molecular tool with which to probe the
molecular mechanism of RAR-mediated gene silencing
more deeply.
TFIIH is a conserved multi-subunit complex involved
primarily in transcriptional initiation and elongation and
is comprised of a 7-subunit core, associated with a
3-subunit CDK-activating kinase (CAK) module. Mutations
in genes encoding subunits of TFIIH involved in nucleotide
excision repair (NER) have been characterized in a variety
of genetic diseases, including xeroderma pigmentosum
(involving XPB/TCRR3), trichothiodystrophy (involving
XPD/TTD/ERCC2) and Cockayne syndrome (involving
XPG/ERCC5).These diseases share a spectrum of
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Figure 4.  Stable forms of RARα in solution and in vivo. A.The RARα LBD exists as a stable monomeric form in solution. B.The functional form
of RARα is as a heterodimer with RXR.The stoichiometry of its interaction with its heterodimeric partner and coactivator is 1:1:1 RAR:RXR:coactivator
peptide.
common symptoms involving the skin (photosensitivity,
skin cancer), development (growth and skeletal
retardation) and neurological deficits. In addition to
phosphorylating RNA Polymerase II, TFIIH has been
shown to phosphorylate the N-terminal domains of several
nuclear receptors, including RARα. Jean-Marc Egly
(Illkirch, France) showed data demonstrating that
residues in XPD played an essential role in anchoring the
binding of the CAK moiety to the core TFIIH. Egly went
on to show that transfection of wild type XPD into the
HD2 cell line, which contains a XPD R683G mutation,
restored RARα phosphorylation concomitant with
restoring the responsiveness of these cells to all-trans
retinoic acid, indicating a critical functional link between
TFIIH phosphorylation of the receptor and its
transcriptional function. Moreover, a RARα containing a
phosphomimetic mutation at one of the serine residues
discussed in Bruno Kieffer’s talk (S77E) was
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Review EMBO Retinoids 2011Figure 5.  A secondary-structure switch controls constitutive gene repression by RAR. The constitutive recruitment of corepressor (CoR) by
RAR is conferred by an extended β-strand (S3) that forms an antiparallel β-sheet with CoR residues (strand β1).This specific interaction allows docking
of helix α1 of the CoR into the coregulator binding groove of RAR otherwise masked by helix H12. Upon agonist binding, a β-strand-to-α-helix transition
allows for helix H11 formation which in turn provokes CoR release, repositioning of the activation helix H12 and coactivator (CoA) recruitment. For
clarity, only the regions involved in the interaction between RAR, CoR and CoA are depicted.
transcriptionally-competent in HD2 cells. Egly next used
a ChIP-based approach to clarify the mechanistic basis
of the involvement of NER factors in transcription. He
described the recruitment of NER proteins at target gene
promoters and showed that transient siRNA-mediated
knockdown of NER factors disrupted patterns of histone
modifications (H3K9/14) and DNA methylation
(H3K4/H3K9) at RAR-regulated promoters. Recalling
Rosenfeld’s earlier talk, Egly showed that XPG mutations
prevented the establishment of a chromatin loop between
the promoter and the terminator during RAR activation,
suggesting that these factors were required for relaxing
DNA and establishing conditions favorable for acetylation
and demethylation. Concluding, he speculated that the
pathological consequences of mutations in NER proteins
in genetic disorders could be ascribed in large part to
their role in establishing transcriptionally-permissive
environments at promoters regulated by a broad range
of transcription factors.
In fibroblasts undergoing in vitro differentiation into
adipocytes, the CRABP family member CRABPI is subject
to alternate up- and downregulation by thyroid hormone
(T3).Li-Na Wei (University of Minnesota, Minneapolis,
USA) discussed recent work in her laboratory
investigating the role of coregulators in mediating this
bidirectional regulation. During the initial phase of
adipogenesis, CRABPI is upregulated in a
TRAP220/MED1-dependent manner, in a mechanism
involving chromatin looping and nucleosome sliding. In
a subsequent second phase of differentiation, CRABPI
is downregulated by T3 in a RIP140/NRIP1-dependent
manner.Wei demonstrated that knockdown of RIP140
during this phase results in T3 activation of the CrabpI
promoter and that its re-expression restored RIP140
repression. Contrasting the loose nucleosomal
organization of the CrabpI promoter during Phase I with
its condensed conformation in Phase II, Wei suggested
that the bidirectional regulation of the CrabpI promoter
was a function of its higher order chromatin organization.
Wei went on to attribute the induction of RIP140 in the
latter stages of adipocyte differentiation to the
downregulation of a microRNA, miR-33, which targets
the 3’-UTR of RIP140. Finally, post-translational
modification of RIP140 was shown to play a role in
mediating its interaction with TRα.Wei showed that
RIP140 was subject to acetylation during adipogenesis,
and that acetylation of K158 and K287 were required for
repression of CrabpI and efficient interaction with TRα.
The identification and characterization of RAR family DNA
binding events in response to retinoid signaling in model
systems is an area of active investigation.Irwin Davidson
(Illkirch, France) described recent genome-wide location
analysis of RARα in mouse embryonic fibroblasts (MEFs)
and embryonic stem (ES) cells [Delacroix et al., 2010].
Using a stably-transfected FLAG-tagged RARα-based
strategy, he demonstrated that there were unique
genomic occupancy sites in MEFs versus ES cells and,
surprisingly, that there were relatively few RAR-occupied
sites – those that were identified were DR1, DR2 or DR5
RAREs.
Davidson progressed to describe ChIP-Seq analysis of
RAR genomic DNA binding events during the RA-induced
development of neural progenitors from embryonic stem
cells via embryoid body cultures, a well-characterized
model system for retinoid signaling. Comparing his
laboratory’s dataset with a similar study in F9 cells
[Lalevee et al., 2011], he found that there were both
overlapping and distinct cistromic signatures for RARα
in both model systems.The most commonly occurring
RAREs were DR0, DR2, DR5 and IR0 in addition to a
novel DR8 motif which was a linear composite of DR2
and DR0 elements. In vitro analysis demonstrated that
DR0 and IR0 elements bound RAR/RXR heterodimers
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independent RAREs on minimal promoters. Parallel
mRNA-seq analysis showed that only a small subset of
RAR-occupied genes were actually regulated by retinoic
acid in embryoid bodies, and that a high frequency of the
induced genes were in fact DR0s – which begs the
question: what is RAR co-operating with if DR0 is not an
independent RAR binding site? Most likely, elements in
neighboring DNA sequences play a role, and future work
will investigate this possibility.
Alternative models of retinoid signaling
Alternative pre-genomic (or “non-genomic”) models of
NR signaling invoke the interface between receptors and
the cellular kinase cascade-mediated signaling pathways
that are initiated by the binding of peptide hormones and
growth factors to cell membrane-bound G-protein coupled
receptors. Many proteins involved in these pathways
contain Src-homology (SH) domains which have
well-characterized roles in signal transduction and
tumorigenesis.Work in the laboratory of Cécile
Rochette-Egly (Illkirch, France) previously
demonstrated the identification of SORBS3/vinexin-β, a
multiple SH3 domain-containing protein involved in
cell-cell adhesion and cytoskeletal function, as a RARγ
corepressor.The interaction between the two proteins
was shown to be mediated by the third SH3 domain
(SH3.3) of vinexin-β and was uncoupled by
phosphorylation of RARγ at two serine residues in its
AF-1 domain.
In the first of the meeting’s short talks, Bruno Kieffer
described recent work in the Rochette-Egly laboratory on
the solution structure of the vinexin-β SH3.3 domain in
complex with a proline-rich domain (PRM) of RARγ that
mediates the interaction with vinexin-β. Analysis of the
structure, in addition to biophysical interrogation of the
effect of serine phosphorylation on the interaction
surfaces of the two moieties, indicated that the
phosphorylation of PRM modulated the conformations of
the interacting partners by reducing their type II
polyproline (PPII) character, an important conformation
in disordered states of proteins. Kieffer concluded by
suggesting that the interaction between the SH3.3 and
PRM domains was modulated by a conformer selection
mechanism.
Pre-genomic activation of kinase signaling cascades by
retinoids was also the subject of a short talk by Aleksandr
Piskunov (IGBMC, Strasbourg, France) of the
Rochette-Egly laboratory. Members of the Gq family of
heterotrimeric G proteins activate β-isoforms of
phospholipase C which in turn catalyzes the hydrolysis
of phosphatidylinositol phosphate to diacylglycerol and
inositol triphosphate, resulting in protein kinase C
activation and mobilization of cellular calcium.
Piskunov showed that RAR agonists induce the
p38/MAPK/MSK1 pathway, and went on to describe an
interaction between Gαq, a member of the Gq family, and
RARα in lipid rafts, which are dynamic microdomains
within the cell membrane lipid bilayer that assemble
specific populations of transmembrane signaling proteins.
Moreover, knockdown of either Gαq or p38 significantly
attenuated RA induction of a reporter gene.
Recapitulating the phosphorylation of RARα serine 77
by kinase signaling cascades alluded to in Jean-Marc
Egly’s talk, Piskunov demonstrated that mutation of these
residues abrogated induction of the RARβ gene by RA,
providing further evidence for the contribution of cellular
kinase signaling pathways to retinoid signaling.
Continuing the theme of non-classical pathways of retinoid
function, Noa Noy (Case Western Reserve University,
Cleveland, USA) described a specific cell-surface RBP
receptor, STRA6, a multitransmembrane domain and
SH2-binding domain protein that is widely expressed in
embryonic development and in adult organ systems, and
previously characterized as a RA-induced gene. Mutations
in STRA6 contribute to a spectrum of congenital
malformations collectively known as Matthew Wood
syndrome [Pasutto et al., 2007], and which include
anophthalmia, congenital heart defects and mental
retardation.
Noy pointed out that ectopic overexpression of RBP
contributes to insulin resistance in animal models, a
somewhat surprising observation given that RA
suppresses obesity and improves insulin resistance. A
clue to this apparent paradox is the crosstalk of STRA6
with the JAK/STAT pathway, a kinase cascade that
mediates cellular response to peptide hormones including
interleukins, interferons, leptin and insulin. RBP-retinol
binding to STRA6 was shown to induce recruitment of
JAK2 and STAT5 by STRA6, as well as triggering
phosphorylation of all three proteins. Moreover,
RBP-retinol induced STAT5, SOCS3 and PPARγ
expression in adipocytes via a mechanism independent
of RA.
In addition to its effects on transcription, Noy
demonstrated that RBP-retinol abrogated activation of
the insulin receptor in a STRA6-, STAT5- and
SOCS3-dependent manner.
Finally, Noy showed that transient recruitment of cellular
retinol binding protein I (CRBPI) to STRA6 upon
retinol-RBP binding was required for retinol signaling,
and that STRA6 signaling was abolished in CRBPI
mutants. Her data sketch the outline of a negative
feedback loop model in which retinol, signaling though
RBP, induces SOCS3 and PPARγ via the JAK/STAT
pathway, resulting in lipid accumulation (via PPARγ) and
downregulation of glucose uptake through antagonism
of insulin-insulin receptor signaling (via SOCS3).
The contribution of CRBP1 to retinoid signaling outlined
in Noy’s talk is interesting in the context of data presented
by Eduardo Farias (New York, USA), who demonstrated
that CRBP-1 impaired c-myc-induced tumorigenesis. His
data indicated opposing effects of RAR isotypes, such
that RARα and RARβ drive cell cycle arrest and
differentiation, whereas RARγ had a repressive effect on
CRBP expression, which is silenced in a wide range of
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RARγ antagonists could provide novel avenues for
treatment of breast cancer.
Developmental biology of retinoid
signaling
The functions of RA and RARs in developmental biology
is a complex interplay of factors ranging from
tissue-selective distribution of RA and its biosynthetic
precursors, expression of RAR isoforms, and the
functional interactions of RARs and RXRs with
transcriptional coregulators to effect co-ordinated
programs of gene activation and repression. Retinol
dehydrogenases (RDH) comprise a family of enzymes
that generate all-trans retinaldehyde from all-trans retinol
during the initial step of retinoic acid biosynthesis.
Downstream of the generation of retinaldehyde substrates
by RDH enzymes is the conversion of these to retinoic
acid by tissue-specific enzymes of the retinaldehyde
dehydrogenase (Raldh) family, which is a key component
in the establishment of morphogenetic gradients of
retinoic acid which play demonstrably crucial roles in early
somitogenesis and neurogenesis.
Tissue-specificity of RA biosynthesis: retinol
dehydrogenases (RDHs) and retinaldehyde
dehydrogenases (RALDHs)
Pascal Dollé (IGBMC, Strasbourg, France) discussed
Cre-Lox conditional knockout model-based studies on
the role of one member of the Rdh family of enzymes,
Rdh10, in early embryogenesis, and the insights these
afford into tissue-specific principles in retinoid signaling.
While Rdh10 null mutants are early embryonic lethal
(E10.5-E12.5), retinoid signaling as reported by a
RARE-Lacz reporter transgene, is significantly
compromised (Figure 6), but not fully abolished – a
reflection of the existence of other members of this
enzyme family possibly acting during tumorigenesis.
Rdh10
-/-  mutant embryos display a number of
developmental defects, including abnormal patterning in
the posterior hindbrain and compaction of the cervical
somitic region. Defects in Rdh10
-/-  mutants were also the
subject of a short talk by Gregg Duester (La Jolla, USA),
who noted impaired forelimb development as well as
defects in early somitic development related to ectopic
Fgf8 expression in the trunk at early stages of
development. Reiterating the tissue-specific nature of
Raldh action, Duester noted that while RA signaling was
compromised in the somitic mesoderm, it was intact in
the neuroectoderm.
Dollé next used rescue experiments involving RA or
retinaldehyde transplacental supplementation of pregnant
mice to determine whether Rdh10 activity was required
for generating tissue-specific distributions of substrates
for embryonic RALDH. He found that RA rescue did not
result in viable Rdh10
-/- mutant embryos, and that these
mutants displayed organogenesis defects characteristic
of RA deficiency in the heart (reduced myocardial
compact zone, epicardial detachment), large vessels
(pulmonary artery atresia) and lungs (absence of left lung,
hypoplastic right lung). In contrast, retinaldehyde
supplementation rescued most developmental defects
and resulted in viable, fertile mutants, suggesting that by
failing to recapitulate the precise tissue-specific gradients
of RA required during development, RA supplementation
is unable to rescue mutants lacking Rdh10.
Figure 6.  Highly diminished RARE-lacZ reporter transgene activity
in an early mouse embryo with a targeted Rdh10 gene disruption.
See text for details.
Dollé concluded with data implicating a member of the
Raldh family, Raldh3, in development of the inner ear
vestibular system. Raldh3 is expressed in discrete areas
of the inner ear, including the spiral ganglia of the cochlea
and specific regions of the vestibular sensory epithelium,
such as the utricle and saccule. Reflecting the role of
these structures in hearing and balance, Raldh
-/- mutant
mice exhibit an abnormal spontaneous circling behavior
and motor skill deficiencies, as well as impaired
development of inner ear vestibular structures. In
particular, there is an absence in these mice of otoconia,
mineralized structures in the utricle and saccule that
provide mass loads for detection of the gravity and linear
acceleration. Dollé concluded by speculating that
RA-based therapeutics might be profitably used to offset
the otoconial degeneration that contributes to a variety
of senescent diseases.
Retinoid signaling in somitic development and
neurogenesis
In vertebrate species, the vertebral column, skeletal
muscle and dermis are derived from embryonic structures
called somites, which are formed by the periodic,
bilaterally symmetrical process of mesodermal
segmentation.The fibroblast growth factor (FGF) pathway
establishes a traveling posterior to anterior gradient of
activity in the presomitic mesoderm such that the
segmentation transcriptional program, involving genes
such as Mesp2, is triggered only in cells exposed to
sufficiently low levels of FGF. Opposed to the FGF
gradient is a RA gradient, and the antagonistic effects of
signaling pathways regulated by these ligands establishes
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catalyzes the synthesis of RA from retinaldehyde in
somitic and rostral presomitic mesoderm; its inhibition by
disulfiram in the chick, or by gene targeting in the mouse,
results in left-right asymmetry of somitogenesis [Vermot
et al., 2005;Vermot and Pourquie, 2005]. Olivier
Pourquié (IGBMC, Strasbourg, France) drew attention
to defects in somitogenesis, including delayed somite
formation on the right side, in a mouse model containing
a mutation in Rere/Atrophin2, previously characterized
as a coregulator for members of the COUP-TF subfamily
of NRs [Wang and Tsai, 2008]. In support of a role for
Atrophin 2 in retinoid signaling, developmental defects in
the Rere/Atrophin2 mutant were strikingly phenocopied
in the Raldh2 mutants. Pourquié proceeded to show data
from a RARE-LacZ mouse crossed into the Atrophin 2
mutant that Atrophin 2 was required for the in vivo
response to RA, and that Atrophin 2 potentiated the
transcriptional response to RA in F9 cells. Supporting
biochemical and in vivo data demonstrated that a complex
comprising Atrophin 2, p300 and COUP-TFII/Nr2f2 was
recruited to RA-responsive genes, and that knockdown
of COUP-TFII and Atrophin 2 abrogated RA signaling.
Pourquié demonstrated that RARs were expressed in the
pre-somitic mesoderm in mouse E8.5 embryos, and that
asymmetric expression of COUP-TFII overlapped with
the RA response domain in the right pre-somitic
mesoderm. Finally, Pourquié discussed multi-dimensional
protein identification technology (MUDPIT) analysis of
Atrophin 2-associated proteins which demonstrated the
existence in the Atrophin 2 interaction network of HDAC1,
HDAC2, p300 and a protein named STRAP
(serine/threonine kinase receptor-associated protein),
mutations in which result in somite desynchronization
defects.
Kate Storey (University of Dundee, Dundee, UK)
continued the developmental theme with a discussion of
neurogenesis, which has several parallels with
somitogenesis in the context of retinoid signaling, notably
the functional antagonism between retinoid- and
FGF-regulated pathways. During neurogenesis, retinoid
signaling, driven in part by Wnt promotion of retinoid
biosynthesis represses FGF action, resolves mesodermal
and neural cell fates and promotes commitment to the
neural cell lineage. Genes involved in neurogenesis
whose expression is subject to mutually opposed
regulation by FGF (repression) and retinoids (induction
(activation) include neurogenin (Ngn)1 and Ngn2, NeuroM
and Crabp1, although these represent only a small
fraction of the major re-organization of transcriptomes
which takes place along the neural axis during
neurogenesis.The FGF/retinoid antagonistic paradigm
so clearly characterized in this context is not a general
rule however, and Storey went on to discuss how retinoid
signaling during embryonic stem (ES) cell differentiation
can, under certain conditions, promote FGF/Erk signaling,
at least transiently. Specifically, RA initially induces a
rapid increase in Erk1/2 signaling via induction of Fgf8,
which ChIP data from the laboratory of Gregg Duester
(La Jolla, USA) implicate as the result of direct binding
of RAR to the Fgf8 promoter. As differentiation progresses
however, there is a net repression of ERk1/2 signaling,
most likely via repression of Fgf4.
Norbert Ghyselinck (IGBMC, Strasbourg, France)
concluded the developmental strand with a discussion of
specific and overlapping roles of RARs during male germ
cell differentiation. Dietary vitamin A deficiency induces
testis degeneration via arrest of spermatogonia
proliferation, which can be reversed by vitamin A or RA
supplementation, indicating that germ cell differentiation
depends on RA signals. Ghyselinck showed that RARγ
is expressed at specific stages during spermatogenesis,
specifically in single cell spermatogonia, as well as in
aligned A spermatogonia in later stages (Figure 7).
Cre-lox-mediated ablation of RARγ or RARα individually
in Sertoli cells is sufficient to induce testis degeneration
through loss of germ cells, although the specific
developmental deficit in each mutant appears to occur at
different points during spermatogenesis. RARα and RARγ
appear to be functionally redundant to some extent in this
context since expression of Stra8, a RA-inducible germ
cell marker, which is undetectable in RARγ-deficient mice,
can be restored by administration of the RARα agonist
BMS753. Observing that ablation of RXRα, RXRβ and
RXRγ in spermatogonia results in a loss of germ cells
similar to that in RARγ and RARα, Ghyselinck proposed
a model in which RARα and RARγ function
cell-autonomously as heterodimers with RXRs.
Retinoid signaling and disease
Consistent with their promotion of exit from the cell cycle
and progression towards differentiated cell fates, retinoids
have anti-proliferative and apoptotic effects and have
found application in a number of inflammatory conditions
including skin disorders, as well as diseases such as
breast cancer and leukemia. Moreover, the functional
integrity of RARs is often subverted in gene translocation
events commonly encountered in leukemias, resulting in
ectopic repression of transcriptional programs involved
in myeloid cell differentiation [Duong and Rochette-Egly,
2011]. Harnessing retinoid signaling pathways has met
with mixed success as a cancer therapeutic strategy,
providing an impetus for more detailed models of retinoid
action in cancer cells and the exploration of alternative
strategies, including epigenomics, for intervention in
retinoid pathways opposing tumor progression.
Breast cancer
Sylvie Mader (Montreal, Canada) described recent
efforts in her laboratory focused on RALDHs as
therapeutic leverage points in breast cancer. RALDH3 is
the predominant RALDH family member in normal breast
tissue, as well as immortalized and breast cancer
epithelial cell lines. Mader noted that the majority of breast
cancer cell lines tested have low RA synthetic capacity,
which correlates with low levels of RALDH3 expression
at both the mRNA and protein levels, a pattern
recapitulated in luminal breast tumors. In contrast,
RALDH3 was highly expressed in normal breast tissue
and mediated retinoic acid biosynthesis in human
immortalized mammary gland 184B5 cells. Given these
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Review EMBO Retinoids 2011Figure 7.  RARγ is expressed in Aal and A1 spermatogonia. External views of seminiferous tubules of wild-type, sexually mature, mice that were
double-immunostained with anti-RARγ (red nuclear signal) and anti-GFRA1 (green membrane signal) antibodies in panel A, with anti-RARγ (red nuclear
signal) and ZBTB16 (green nuclear signal) antibodies in panel B, and with anti-RARγ (red nuclear signal) and anti-KIT (green membrane signal)
antibodies in panel C. Legend: As, Aal, and A1 indicate A single, A aligned and A1 spermatogonia, respectively. Bar: 50 µm.
observations, Mader next asked whether ectopic RALDH
expression might inhibit growth and proliferation of breast
cancer cell lines and luminal tumors. RALDH3 was
capable of inducing G0/G1 arrest in tumorigenic SKBR3
cells, inhibited colony formation in MCF-7 breast cancer
cells and retarded tumor growth in MCF-7 xenograft
models. At the transcriptional level, Mader demonstrated
a remarkable overlap between patterns of gene
expression in luminal cells exposed to retinoic acid or
expressing RALDH3, resulting in the activation of
luminal-specific transcription factors and of
anti-proliferative and pro-apoptotic gene networks.The
17β-estradiol/ER proliferative paradigm is well established
in models of epithelial breast cancer, and Mader’s closing
remarks illuminated the dynamic antagonism that exists
between this signaling conduit and that of retinoids. She
observed that RALDH3 expression is blocked by
17β-estradiol in an ERα-dependent manner, while this
effect is reversed by anti-estrogens such as Fulvestrant
and Tamoxifen.
A number of models exist for the development of
resistance by breast tumors to treatment with Tamoxifen,
one of which invokes the role of a cancer stem cell
population in the generation of novel
chemotherapeutically-resistant cell lineages in tumors.
Maria del Mar Vivanco (Bilbao, Spain) described recent
work in her laboratory which sheds light on the role of
tumor stem cells using a Tamoxifen-resistant MCF-7 cell
line.These cells resemble progenitor cells in their
expression of high levels of Sox2, a member of the
SRY-related HMG-box family of transcription factors
required for the maintenance of cancer stem cells. Ectopic
overexpression of Sox2 was shown to confer increased
resistance of cells to the anti-proliferative effects of
Tamoxifen, and clinically, Sox2 was more highly
expressed in recurrent tumors than in primary tumors.
While most of the speakers reiterated the
pro-differentiative, antiproliferative effects of retinoid
signaling, Vincent Giguère (Montreal, Canada) sounded
a dissonant note by discussing data casting RA and RARβ
as cancer promoters. RARβ null mice exhibit delayed
mammary gland development and tumorigenesis is
delayed in a MMTV-ErbB2 model in a RARβ null
background. Giguère cited downregulation of the
Cxc12/SDF-1 pathway in RARβ null mice as a possible
mechanistic basis for RARβ’s promotion of tumorigenesis.
While provocative, Giguère’s results did not exclude the
possibility that there is developmental overcompensation
for germline loss of RARβ from other RAR isoforms, a
possibility given the overlapping functions of members of
this subfamily, and a conditional mammary gland
knockout of RARβ would more clearly address the nature
of its role in breast cancer.
Leukemias
Hematopoiesis is the continuous formation of all blood
cell types from hematopoietic stem cells residing in the
bone marrow. Cell fates during hematopoiesis are a
function of both extracellular signaling networks mediated
by soluble growth factors and their receptors, as well as
specific transcriptomic fingerprints triggered in individual
cell populations in response to these signaling events. In
myeloid leukemia, the mechanisms that normally promote
differentiation into the diverse myeloid lineages are
disrupted, leading to pathological accumulation of
immature hematopoietic cell types.
Henk Stunnenberg (Nijmegen,The Netherlands)
opened with an overview of the European Union-funded
BLUEPRINT of Hematopoietic Epigenomes, a team
science endeavor that aims to generate genomic DNA
sequence, epigenomic and transcriptomic datasets from
about 60 distinct types of primary hematopoietic cells and
blood cancer subtypes. Oncofusions involving AML and
PML proteins are well characterized in leukemias: the
fusion protein, promyelocytic leukemia (PML)-retinoic
acid receptor-α (RARA), initiates acute promyelocytic
leukemia (APL) through both a block to differentiation
and increased self-renewal of leukemic progenitor cells.
Similarly, the fusion of AML1 and the transcriptional
corepressor ETO (RUNX1T1) through a t(8;21)
translocation is a frequent genetic lesion in acute myeloid
leukemia (AML). Stunnenberg posed the questions: where
do these oncofusion proteins bind, do they alter the
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common mechanisms exist by which they achieve these
ends? Stunnenberg described a comparison of AML1
and AML1/ETO sites in SKNO/Kasumi cells and AML
patient blasts, and demonstrated a redistribution of targets
from gene promoters in the case of AML1 towards introns
and intergenic regions for AML1/ETO. Stunnenberg
pointed out that AML1/ETO bound preferentially to
multimerized sites, and speculated that this was due to
the oligomerization properties of AML1, previously shown
to be required for the interaction of ETO with
transcriptional corepressors. Members of the erythroblast
transformation-specific (ETS) family of transcription
factors are key regulators of embryonic development, cell
proliferation, differentiation, angiogenesis, inflammation,
and apoptosis. Stunnenberg described an overlap
between binding sites for ERG, a member of the ETS
family, and AML1-ETO in U937 cells, and highlighted the
fact that elevated expression of ERG in AML was
associated with poor prognosis in the disease. Addressing
the epigenomic consequences of AML1-ETO,
Stunnenberg demonstrated that AML1/ETO binding in
U937 cells was associated with local hypoacetylation,
consistent with the association of ETO with corepressors.
Drawing parallels between the AML1/ETO and
PML/RARα paradigms, he described extensive overlap
between the binding sites of the two fusion proteins. He
concluded by speculating that a common mechanism for
disease progression was the recruitment of the oncofusion
proteins to promoters of ETS family-regulated genes
encoding proteins required for myeloid differentiation,
and the subsequent epigenomic silencing of these genes
via a mechanism involving association of corepressors
with the fusion proteins.
In addition to the well-characterized functions of
transcription factors and coregulators, there is an
increasing recognition of miRNAs as key players in
orchestrating specific transcriptional endpoints during
hematopoiesis.Clara Nervi (University of Rome, Rome,
Italy) focused on the role of one such miRNA, miR-223,
in normal hematopoietic development as well as in the
deficits in differentiation characteristic of the progression
of leukemic cells, and the interface between this miRNA
and retinoid signaling. Administration of RA in HL60 cells
results in the association of miR-223 with the miRNA
processing ribonuclease Dicer1, a key step in the
processing of miRNAs. Nervi showed that ectopic
expression of miR-223 potentiated granulocytic
differentiation of ALP-NB4 cells, and that the AML1/ETO
oncofusion targeted miR-223 for heterochromatic
silencing.
Further evidence for the functional interaction of miR-223
and AML1/ETO in hematopoietic pathologies was
provided by the similar myeloproliferative disorders in
miR-223 knockout and AM1/ETO transgenic mice. Nervi
provided evidence that one of the targets of miR-223 in
this context was NFIA: treatment of HL60 cells with RA
resulted in silencing of the NFIA promoter accompanied
by recruitment of miR-223. Moreover, NFIA was
downregulated in HL60 cells following overexpression of
miR-223. Progressing to the clinical setting, Nervi
demonstrated that expression of miR-223 in primary
blasts from AML patients restored myeloid differentiation.
Failure of tumors to respond to retinoid therapy is a
common clinical observation, suggesting that establishing
an environment more receptive to retinoid signaling might
be a profitable approach in treatment of the disease. In
this context, Christine Chomienne (Hôpital St Louis,
Paris, France) discussed epigenetic strategies to
enhance RAR promoter permissiveness as a therapeutic
strategy in leukemogenesis. She demonstrated that
non-responsiveness of thyroid cancer cells to RA was
associated with reduced histone acetylation and increased
DNA methylation of the RARβ promoter.The combination
of RA with a histone deacetylase inhibitor resulted in
increased expression of RARβ in these cells. In the
clinical setting, the combination of RA with histone
deacetylases such as valproic acid in non-APL leukemias
was associated with complete remission in older patients,
albeit with a modest response rate.
Hugues deThé (Hôpital St Louis, Paris, France)
concluded the meeting with a discussion of data on the
molecular mechanisms of RA and arsenic trioxide (As2O3)
therapy in APL, a combination therapy that has become
standard of care for the disease, with an emphasis on
the PML-RARα oncofusion. Both RA and As2O3 degrade
PML-RARα, and synergize in the treatment of APL in
mice, radically extending their life span.This synergy
arises from the fact that they engage parallel
proteasome-dependent PML/RARα degradation
pathways, As2O3 targeting the PML moiety of the
oncofusion for sumoylation and RA targeting the RAR
portion of the molecule in a manner evoking the targeting
of ERα for degradation by Fulvestrant. deThé highlighted
the role of a CC motif in the B2 box region of PML,
pointing out that amino acid variability in this region of
the molecule, secondary to mis-sense mutations in the
PML gene, was a critical determinant of the
responsiveness to As2O3 treatment. deThé invoked a
derepression model for PML-RARα-targeted therapy,
suggesting that loss of PML-RAR was the motive force
behind the reversion to a default myeloid differentiation
pathway.
Conclusions
This brief, focused meeting reflected the ongoing efforts
of a highly active clinical and translational global research
community and the contributions that it continues to make
not only in the context of retinoid signaling, but to the
broader picture of nuclear receptor signaling. It reiterated
the myriad critical junctures along the axis of retinoid
signaling – retinoic acid biosynthesis, the interaction
between ligand and receptor, or the action of RAR
coregulators, has been shown to have profound
consequences both in early embryonic development and
in a variety of human pathologies. In addition to these
better characterized components, compelling evidence
was made for non-coding RNAs, DNA looping and
excision repair mechanisms, as well as epigenomic
programming of promoters, as emerging mechanistic
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context of signal transduction by the NR superfamily.
Finally, the field has shown itself to be highly active in the
translation of mechanistic principles of retinoid signaling
into strategies that are showing promise in the treatment
of myriad neoplastic and inflammatory conditions, and
one can justifiably anticipate further exciting advances in
the mechanism, biology and pathology of retinoid
signaling in the coming years.
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